TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia
Brief Summary: This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of clozapine in 40 patients with schizophrenia or schizoaffective disorder. Modafinil will be initiated at 100 mg/d. After 2 weeks, the study drug may be increased to 200 mg/d and after 4 weeks, study drug may be increased to a maximum of 300 mg/d. Dose escalation will be based upon persistence of sedation versus emergence of side effects.


Options:
A: Arm Label: 50 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 100 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 50 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 100 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: modafinil; Type: EXPERIMENTAL; Interventions: Drug: modafinil | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: modafinil; Assigned to Arm(s): modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil (Nuvigil) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil (Nuvigil); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: 150 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 250 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 150 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Matching Placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 250 mg/day armodafinil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
Brief Summary: The purpose of this study is to determine whether treatment with D9421-C for 8 weeks in Japanese patients with mild to moderate active Crohn's disease will improve their symptoms of Crohn's disease and quality of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 9mg | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 15mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D9421-C, 9mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: D9421-C, 15mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): B
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB
Brief Summary: Evaluate the effect of VESIcare® on symptom bother for subjects with OAB


Options:
A: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin Succinate; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-3001a | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: DR-3001b | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: DR-3001a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: DR-3001b; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Vibegron + Placebo to match Tolterodine; Type: EXPERIMENTAL; Interventions: Drug: vibegron, Drug: Tolterodine placebo | Arm Label: Placebo to match vibegron + Placebo to match Tolterodine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine placebo | Arm Label: Tolterodine + Placebo to match vibegron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine Tartrate ER | Intervention Type: DRUG; Name: vibegron; Assigned to Arm(s): Vibegron + Placebo to match Tolterodine | Intervention Type: DRUG; Name: Vibegron placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine Tartrate ER; Assigned to Arm(s): Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Vibegron + Placebo to match Tolterodine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Comparison of the Effect of Frequent Oral Dosing Versus Constant IV Infusion of Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers
Brief Summary: Patients with bleeding ulcers identified by endoscopy will be randomly assigned to receive an acid-blocking drug (called a proton pump inhibitor \[PPI\]) either by mouth every 3 hours for 24 hours or intravenously (IV) by constant infusion for 24 hours. A pH probe in the stomach will be used to determine intragastric pH (a measure of the acid production in the stomach) at baseline and during the 24 hours of therapy. The purpose of the study is to determine if the continuous intravenous administration of the drug provides better reduction of acid in the stomach than the oral administration.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Intervention Type: DRUG; Name: Proton pump inhibitor (lansoprazole); Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: High dose pantoprazole infusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard dose pantoprazole infusion | Intervention Type: DRUG; Name: High dose pantoprazole infusion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard dose pantoprazole infusion; Assigned to Arm(s): 2
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): 2
D: Arm Label: lansoprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: lansoprazole | Arm Label: esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: lansoprazole; Assigned to Arm(s): lansoprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)
Brief Summary: Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation. Recently there were report of beneficial effect of cilostazol like vasodilation, lipid metabolism, and cytokine production. But there were few clinical studies that support these effects of cilostazol. The purpose of this study is to evaluate the vasodilatory and anti-inflammatory effect of cilostazol presented by PWV and plasma adipocytokines.


Options:
A: Arm Label: Cilostazol + L-Carnitine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Levocarnitine tartrate, Drug: cilostazol | Arm Label: Cilostazol + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cilostazol | Intervention Type: DIETARY_SUPPLEMENT; Name: Levocarnitine tartrate; Assigned to Arm(s): Cilostazol + L-Carnitine | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): Cilostazol + L-Carnitine, Cilostazol + Placebo
B: Arm Label: Cilostazol; Type: EXPERIMENTAL; Interventions: Drug: cilostazol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): Cilostazol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: low dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: mid dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: high dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cilostazol 100 mg BID | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: K-134; Assigned to Arm(s): high dose K-134, low dose K-134, mid dose K-134 | Intervention Type: DRUG; Name: Cilostazol 100 mg BID; Assigned to Arm(s): Comparator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Person-centered follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Person-centered follow up | Arm Label: Standard follow up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Person-centered follow up; Assigned to Arm(s): Person-centered follow up

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab Escape arm; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab Escape arm, Bimekizumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab cohort, Placebo
B: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo

Answer: D